FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).
Related news for (GNTA)
- Next Entertainment Boom Ignited, Blowout Earnings, Bio Science, and Merger News, as Wall Street Turns Up the Volume
- Today’s Top Performers: MoBot’s Market Review 10/24/25 07:00 AM
- MoBot alert highlights: NASDAQ: VIOT, NASDAQ: GNTA, NASDAQ: QLGN, NASDAQ: VIVK, NASDAQ: ADTX (10/24/25 06:00 AM)
- MoBot’s Stock Market Highlights – 10/24/25 05:00 AM
- Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
